OVERVIEW
Protalex is developing a series of bioregulatory compounds based on the principle of normalizing the activities of immune cells.
When tested in autoimmune disease models, the natural compound, PRTX-100 (Protalex’s lead compound), reversed the pathologic process, resulting in restoration and maintenance of normal, healthy tissue. Protalex intends to bring its knowledge of this biotechnology to bear on a range of serious autoimmune diseases that affect millions of people. Its initial focus is on idiopathic thrombocytopenic purpura and rheumatoid arthritis, however, Protalex’s unique technology is applicable to a wide range of autoimmune disorders. The Company intends to investigate the utility of PRTX-100 and a second generation compound, PRTX-200, as treatments for Systemic Lupus Erythematosus (SLE), various inflammatory bowel diseases, insulin-dependent diabetes mellitus, multiple sclerosis, and other orphan indications such as Anti-Phospholipid Syndrome (APS) (also known as Hughes Syndrome, a disorder characterized by multiple different antibodies that are associated with both arterial and venous thrombosis), Graves’ disease (characterized by over-activity of the thyroid gland) and Pemphigus (a rare blistering disorder of the skin).